Business Context and Reporting Period
This Form 8-K Current Report was filed by Camp4 Therapeutics Corp on March 18, 2026. The filing discloses corporate governance changes, specifically the appointment of a new director and amendments to the non-employee director compensation policy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: Michael MacLean was appointed as a Class III director, effective April 1, 2026. He was also appointed to the Audit Committee and Compensation Committee.
- Compensation Policy Amendment: The Board approved an amendment to the Non-Employee Director Compensation Policy. New directors appointed on or after April 1, 2026, will receive an option to purchase 56,000 shares of common stock under the 2024 Equity Incentive Plan, vesting monthly over three years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. Management commentary is limited to the rationale for Mr. MacLean's appointment, citing his over 35 years of financial leadership experience in biotechnology and life sciences, including roles as CFO at Avidity Biosciences, Akcea Therapeutics, and PureTech Health.
Investor Verification Checklist
- Verify the effective date of Michael MacLean's appointment (April 1, 2026) and his specific committee assignments.
- Confirm the terms of the stock option grant (56,000 shares, 3-year vesting) under the 2024 Equity Incentive Plan.
- Review the standard form of indemnification agreement referenced in the filing.
- Check for any related party transactions exceeding $120,000, which the filing states do not currently exist.